DEC 17, 2020 4:00 PM PST

Molecular Mechanism Behind Ketamine for Depression Discovered

WRITTEN BY: Annie Lennon

Over 30% of people with major depressive disorder are resistant to serotonin reuptake inhibitors (SSRI's), the current frontline prescription drug for the condition. Researchers are thus scrambling to find an alternative. Now, researchers from Canada have found that ketamine works against depression via a group of proteins involved in memory formation. Their discovery will go on to create better treatments for some patients with major depression. 

Ketamine was initially approved by the FDA as an anaesthetic in the 1970's. However, research has since found that it is also effective against depression. Unlike standard treatments for the condition, which typically take weeks to have an effect, ketamine works within hours. And now, researchers have uncovered one of the molecular mechanisms behind this effect. 

For their study, they examined the effects of ketamine on behavior and neuronal activity in mice. They used genetic tools to remove 4E-BP proteins (important for switching protein synthesis for memory formation on or off) from excitatory neurons (which make up most of the neurons in certain areas of the brain) and inhibitory neurons (those which control excitatory neurons) to see how ketamine worked in each case. 

In the end, the found that when 4E-BP proteins were absent from both types of neurons, ketamine was unable to relieve depressive behaviors and neuronal patterns. This came as these proteins were able to turn protein synthesis necessary for memory formation on or off. 

"Too many decisions continue to be made by a trial-and-error approach that can prolong the suffering of patients and affect their quality of life," says co-author of the study, Argel Aguilar-Valles. 

"Our discovery has the potential to bring us closer to find a safer alternative to ketamine, and ultimately to a personalized medicine approach, where medical treatments are tailored to the individual characteristics of each patient."

 

Sources: Neuroscience NewsNature

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
NOV 02, 2020
Drug Discovery & Development
Beetroot Peptide Shows Promise in Treating Inflammatory Diseases
NOV 02, 2020
Beetroot Peptide Shows Promise in Treating Inflammatory Diseases
Researchers from the Medical Univesity of Vienna in Austria have found that a peptide (a small protein molecule) found i ...
NOV 09, 2020
Microbiology
Fighting COVID-19 with Help From Llamas
NOV 09, 2020
Fighting COVID-19 with Help From Llamas
Camelids, which include llamas, alpacas and camels have immune systems that generate two kinds of antibodies when confro ...
NOV 12, 2020
Technology
The Crossover of Virtual Reality and Drug Discovery
NOV 12, 2020
The Crossover of Virtual Reality and Drug Discovery
Researchers have recently developed a unique virtual reality (VR) tool that can help in drug development? Particularly, ...
DEC 04, 2020
Drug Discovery & Development
OTC Drug Found Safe for Multiple Myeloma
DEC 04, 2020
OTC Drug Found Safe for Multiple Myeloma
Injecting the immune-boosting drug ‘teclistamab’ was found to be safe and effective in patients with relapse ...
DEC 09, 2020
Drug Discovery & Development
Rapid-Release Capsule for IBS
DEC 09, 2020
Rapid-Release Capsule for IBS
Researchers have developed a rapid-release capsule to treat symptoms of irritable bowel syndrome with constipation (IBS- ...
DEC 29, 2020
Cannabis Sciences
What Happens When You Combine Cannabis with Psychedelics?
DEC 29, 2020
What Happens When You Combine Cannabis with Psychedelics?
Despite the growing popularity of cannabis and psychedelics, there is a shortage of research on how the two interact. Be ...
Loading Comments...